Benign Conditions

"As we look back over the past 5 decades in urology, bladder dysfunction, particularly inadequate contraction, is still a disorder with unmet medical need, for which new treatments are crucial," writes Gopal H. Badlani, MD.

Fluoroquinolone could increase the risk of altered mental status and hospitalizations for older patients with advanced chronic kidney disease.

Addressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.

Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence.

In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.

In this interview, Ashley Winter, MD, discusses why urologists should play a role in the management of STDs and STIs, especially when it comes to destigmatizing them.

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.

In the pivotal phase 3 DAPA-CKD trial, dapagliflozin reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or cardiovascular or renal death by 39%.

The FDA’s decision not to approve roxadustat follows a vote from the agency’s Cardiovascular and Renal Drugs Advisory Committee that the drug’s benefit-risk profile does not support approval.

The FDA has issued a complete response letter regarding a new drug application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

The mechanism of action of roxadustat differs from that of erythropoietin stimulating agents.

Lumasiran is the first drug approved by the FDA for the treatment of patients with primary hyperoxaluria type 1.

The application for the targeted release formulation of budesonide is supported by data from the phase 3 NefIgArd trial and the phase 2 NEFIGAN trial.

The retrospective study compared reintervention rates in the 4 standard surgical interventions for lower urinary tract symptoms due to benign prostatic obstruction.

Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.

Lobe enucleation efficiency is significantly better with Moses technology, investigators report.

Compared with the open procedure, robot-assisted simple prostatectomy was associated with a shorter median hospital stay.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

Next-generation DNA sequencing can identify more than 50,000 microorganisms.

Bradley A. Erickson, MD, MS, discusses what he and his co-authors learned from developing a mobile app for assessing urologic chronic pelvic pain syndrome.

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

The Optilume drug-coated balloon catheter system has been approved for use in European patients with urethral strictures.

Julia Beth Finkelstein, MD, MPH, CPPS, and colleagues evaluated the safety and costs associated with telemedicine appointments for pediatric urologic patients.

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Retreatment rates were low with both aquablation and transurethral resection of the prostate.

In this interview, Jeffrey Weiss, MD, also describes “most exciting area in nocturia research.”

In this interview with Urology Times® Editorial Consultant Gopal Badlani, MD, Weiss also stresses the importance of a 24-hour voiding diary.

The Soltive Laser System, which uses thulium fiber laser technology, has been shown to generate finer particulate and dusted stones in half the time as a standard holmium yttrium aluminium garnet laser.